兰卫医学
(301060)
| 流通市值：37.28亿 | | | 总市值：41.45亿 |
| 流通股本：3.60亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,102,095,711.13 | 759,388,284.42 | 350,884,969.11 | 1,742,181,004.45 |
| 营业收入 | 1,102,095,711.13 | 759,388,284.42 | 350,884,969.11 | 1,742,181,004.45 |
| 二、营业总成本 | 1,065,770,911.06 | 737,940,752 | 350,095,343.91 | 1,734,032,450.01 |
| 营业成本 | 835,515,526.13 | 588,178,035.39 | 280,874,494.68 | 1,357,465,426.08 |
| 税金及附加 | 4,083,362.65 | 2,852,029.49 | 1,412,361.62 | 6,565,496.97 |
| 销售费用 | 59,573,189.24 | 38,854,498.53 | 18,263,941.75 | 88,946,942.94 |
| 管理费用 | 126,048,137.93 | 81,307,833.46 | 37,305,755.7 | 215,302,090.53 |
| 研发费用 | 38,357,166.74 | 24,609,239.63 | 11,490,853.98 | 59,972,581.74 |
| 财务费用 | 2,193,528.37 | 2,139,115.5 | 747,936.18 | 5,779,911.75 |
| 其中:利息费用 | 4,839,102.3 | 3,585,277.82 | 3,291,839.37 | 10,808,964.34 |
| 其中:利息收入 | 2,994,059.79 | 1,733,989.57 | 2,753,571.5 | 6,246,244.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 51,715.73 | 51,715.73 | 51,715.73 | - |
| 加:投资收益 | -767,864.78 | -1,822,039.79 | 298,518.6 | 4,379,506.45 |
| 资产处置收益 | -500,711.14 | -31,469.29 | 55,506.81 | 5,667,528.69 |
| 资产减值损失(新) | -3,236,727.51 | -6,495,306.77 | -7,487,033.3 | -79,018,069.7 |
| 信用减值损失(新) | -13,501,833.7 | -12,174,034.53 | -2,345,983.23 | -24,388,185.28 |
| 其他收益 | 6,600,265.04 | 4,585,302.9 | 1,964,123.69 | 15,902,748.65 |
| 四、营业利润 | 24,969,643.71 | 5,561,700.67 | -6,673,526.5 | -69,307,916.75 |
| 加:营业外收入 | 942,397.83 | 732,026.93 | 41,095.18 | 1,513,479.16 |
| 减:营业外支出 | 4,463,808.51 | 2,517,386.44 | 455,104.06 | 35,021,601.71 |
| 五、利润总额 | 21,448,233.03 | 3,776,341.16 | -7,087,535.38 | -102,816,039.3 |
| 减:所得税费用 | 11,240,980.75 | 7,583,042.18 | 1,338,717.6 | -4,225,861.21 |
| 六、净利润 | 10,207,252.28 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 10,207,252.28 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -667,742.31 | -5,783,174.11 | -8,080,860.79 | -109,436,220.8 |
| 少数股东损益 | 10,874,994.59 | 1,976,473.09 | -345,392.19 | 10,846,042.71 |
| 扣除非经常损益后的净利润 | -7,537,499.9 | -7,643,223.39 | -10,874,027.14 | -109,080,713.7 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | -0.01 | -0.02 | -0.27 |
| (二)稀释每股收益 | 0 | -0.01 | -0.02 | -0.27 |
| 九、综合收益总额 | 10,207,252.28 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 |
| 归属于母公司股东的综合收益总额 | -667,742.31 | -5,783,174.11 | -8,080,860.79 | -109,436,220.8 |
| 归属于少数股东的综合收益总额 | 10,874,994.59 | 1,976,473.09 | -345,392.19 | 10,846,042.71 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-28 | 2025-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |